GAITHERSBURG, Md., Dec. 2, 2014 /PRNewswire-iReach/ -- Panacea Pharmaceuticals, Inc. presents a paper regarding the enhanced detection of its cancer tumor marker HAAH in the exosomes of human serum at the American Association for Cancer Research meeting in Orlando, FL held December 1-4, 2014. The paper is titled:
Photo - http://photos.prnewswire.com/prnh/20141202/161840
“Quantitative Recovery of Aspartyl (Asparaginyl) beta Hydroxylase (HAAH) from an Exosome-Like Fraction of Human Sera from Cancer Patients”
Panacea has identified HAAH as a promising cancer biomarker target for diagnostic and therapeutic applications. Highly sensitive and specific (>90 % each parameter) detection of HAAH in the sera of cancer patients is accomplished by Panacea’s proprietary ELISA technology. However, sera from some patients exhibit assay interference. Our work to overcome this interference has identified that HAAH is present in exosomes in serum and can be recovered quantitatively by a simple serum extraction method. This observation will facilitate further improvement of the sensitivity of the serodiagnostic test, while maintaining the assay specificity.
“We are excited to report this signficant advance in the understanding of the serum compartmentation of the HAAH cancer biomarker”, said Hossein Ghanbari, Ph.D., CEO and CSO of Panacea. “This discovery will allow us to provide a highly accurate and sensitive diagnostic tool for the detection and monitoring of cancer and will provide a useful cancer management tool for oncologists”.
Panacea Pharmaceuticals is focused on the development and commercialization of HAAH-based diagnostic tests and therapeutic products for cancer, including our HAAH ELISA, a human monoclonal antbody for tumor imaging and a therapeutic nanoparticle vaccine. In addition, Panacea’s anti-cancer portfolio includes small molecule neuroprotectant compounds for the prevention of chemotherapy-induced cognitive impairment (“chemo-brain”) and peripheral neuropathy.
Media Contact:Steven Fuller, Panacea Pharmaceuticals, Inc., 240-454-8010, sfuller@panaceapharma.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Panacea Pharmaceuticals, Inc.
Help employers find you! Check out all the jobs and post your resume.
